Pazopanib improves progression-free survival without impairing HRQOL

(European Organisation for Research and Treatment of Cancer) Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.

http://www.eurekalert.org/pub_releases/2015-07/eofr-pip070615.php

Source: EurekAlert! - Cancer - July 6, 2015 Category: Cancer & Oncology Source Type: news